Viking Therapeutics, Inc.(VKTX)今日盘中大涨6.71%,引发市场关注。
Viking Therapeutics是一家专门从事以代谢和内分泌失调为重点的生物制药开发公司。公司的肥胖症候选药物VK2735最新进展获得华尔街分析师一致看好,成为股价大涨的主要利好推动力。
分析师预期,Viking Therapeutics即将公布的VK2735临床数据将带来利好新闻。此前,摩根大通曾发布报告,首次给予Viking Therapeutics"买入"评级,并将该股列入积极催化剂观察名单,期待VK2735数据将推动股价上涨。
同时,Viking Therapeutics本季度财务业绩也超出市场预期。公司良好的业务发展状况,以及所在医疗保健行业整体向好的走势,也为股价大涨增添了动力。机构评级方面,当前100%的券商都给予Viking Therapeutics买入建议,反映了市场对公司前景的看好。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.